{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.31","value":"61.9"},{"groupId":"OG001","spread":"22.21","value":"56.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Global Health Status/QoL: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.71","value":"-5.8"},{"groupId":"OG001","spread":"20.46","value":"-9.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Global Health Status/QoL: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.69","value":"73.2"},{"groupId":"OG001","spread":"21.24","value":"71.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Physical Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.07","value":"-4.6"},{"groupId":"OG001","spread":"20.54","value":"-13.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Physical Functioning: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.35","value":"68.1"},{"groupId":"OG001","spread":"30.31","value":"65.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Role Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.87","value":"-8.4"},{"groupId":"OG001","spread":"29.83","value":"-18.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"title":"Role Functioning: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.33","value":"71.9"},{"groupId":"OG001","spread":"23.87","value":"68.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Emotional Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.02","value":"-3.8"},{"groupId":"OG001","spread":"22.16","value":"-3.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Emotional Functioning: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.08","value":"81.7"},{"groupId":"OG001","spread":"23.91","value":"79.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Cognitive Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.81","value":"-7.5"},{"groupId":"OG001","spread":"22.92","value":"-6.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Cognitive Functioning: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.96","value":"69.1"},{"groupId":"OG001","spread":"26.88","value":"69.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"title":"Social Functioning: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.52","value":"-5.9"},{"groupId":"OG001","spread":"29.60","value":"-10.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"title":"Social Functioning: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.72","value":"39.4"},{"groupId":"OG001","spread":"25.99","value":"42.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Fatigue: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.93","value":"5.1"},{"groupId":"OG001","spread":"23.05","value":"14.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Fatigue: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.36","value":"8.3"},{"groupId":"OG001","spread":"18.26","value":"10.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Nausea and Vomiting: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.93","value":"5.2"},{"groupId":"OG001","spread":"23.33","value":"7.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Nausea and Vomiting: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.54","value":"37.9"},{"groupId":"OG001","spread":"30.38","value":"42.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Pain: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.84","value":"2.8"},{"groupId":"OG001","spread":"30.33","value":"6.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Pain: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.36","value":"25.4"},{"groupId":"OG001","spread":"29.09","value":"25.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Dyspnoea: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.91","value":"0.7"},{"groupId":"OG001","spread":"28.95","value":"5.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"title":"Dyspnoea: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.95","value":"33.2"},{"groupId":"OG001","spread":"31.42","value":"35.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Insomnia: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.67","value":"4.4"},{"groupId":"OG001","spread":"32.24","value":"-4.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Insomnia: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.34","value":"20.8"},{"groupId":"OG001","spread":"28.68","value":"25.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Appetite Loss: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.78","value":"3.1"},{"groupId":"OG001","spread":"30.32","value":"10.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Appetite Loss: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.18","value":"17.7"},{"groupId":"OG001","spread":"26.56","value":"19.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Constipation: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.92","value":"3.3"},{"groupId":"OG001","spread":"31.27","value":"7.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Constipation: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.73","value":"7.2"},{"groupId":"OG001","spread":"15.69","value":"6.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Diarrhoea: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.56","value":"11.4"},{"groupId":"OG001","spread":"22.46","value":"3.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Diarrhoea: Change From Baseline at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.39","value":"27.6"},{"groupId":"OG001","spread":"30.91","value":"22.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Financial Difficulties: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.09","value":"0.4"},{"groupId":"OG001","spread":"23.54","value":"1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Financial Difficulties: Change From Baseline at EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"224"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 is a questionnaire to assess quality of life (QoL), it is composed of 30 questions (items) resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, pain), and 6 single items (dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status indicate a better quality of life; a positive change from baseline indicates improvement. Lower scores on the symptom and single-item scales indicate a better quality of life; a negative change from baseline indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received sacituzumab govitecan 10 mg/kg of body weight, administered as a slow IV infusion either by gravity or with an infusion pump on Days 1 and 8 of a 21-day treatment cycle for up to 29.6 months. Infusion rate for the first 15 minutes started with 50 mg/hour or less with a subsequent infusion of 100 to 200 mg/hour up to a maximum recommended rate (advanced every 15 to 30 minutes) of 500 mg/hour with a subsequent infusion of 1000 mg/hour. Participants continued treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable AEs.","id":"OG000","title":"Sacituzumab Govitecan"},{"description":"Participants received TPC (ie, eribulin, capecitabine, gemcitabine, or vinorelbine), administered as a single-agent regimen that was selected by the investigator before participant randomization. Participants continued treatment until progression of disease requiring treatment discontinuation or occurrence of unacceptable AEs.\n\nEribulin was administered IV over 2 to 5 minutes at a dose 1.4 mg/m\\^2 at North American sites and 1.23 mg/m\\^2 at European sites on Days 1 and 8 of a 21-day cycle for up to 15.3 months. Lower doses were administered on the same schedule to participants with moderate hepatic impairment (ie, Child-Pugh B; 0.7 mg/m\\^2 and 0.67 mg/m\\^2 for North American and European sites, respectively).\n\nCapecitabine 1000 to 1250 mg/m\\^2 was administered in a 21-day cycle, with capecitabine administered orally twice daily for 2 weeks followed by 1-week rest period for up to 10.6 months.\n\nGemcitabine 800 to 1200 mg/m\\^2 was administered IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle for up to 8.1 months.\n\nVinorelbine 25 mg/m\\^2 was administered as a weekly IV injection over 6-10 minutes for up to 11.5 months. Vinorelbine was not allowed as TPC for any participant with Grade 2 neuropathy.","id":"OG001","title":"Treatment of Physician's Choice (TPC)"}],"paramType":"MEAN","populationDescription":"Participants in the Safety analysis set with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline; End of Treatment (EOT) (up to 29.6 months)","title":"Change From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}